Stay updated on Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial page
- Check4 days agoChange DetectedAdded the Locations section with a Massachusetts site; removed the HHS Vulnerability Disclosure link and the previous Massachusetts Locations entry, and updated the revision to v3.3.3.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page adds a note that publications are automatically filled from PubMed and updates the revision from v3.2.0 to v3.3.2; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check32 days agoChange DetectedThe deletions remove a government funding lapse notice that stated NIH operations may be affected and directed readers to updates, and the notice is no longer visible on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check54 days agoChange DetectedThe page shows a recent administrative update to Study Record Dates (Last Update Posted 2025-06-19) with no changes to study design, eligibility criteria, or outcomes; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check76 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference2%

- Check83 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Thyroid Cancer Clinical Trial page.